Amerikanische Gesellschaft für Hirudotherapie

Aeromonas spp. infections: retrospective study in Nimes University Hospital, 1997-2004

Retrospective study published in Pathol Biol Paris (2008)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSicherheit & InfektionskontrolleKlinische StudienFraisse T et al. · Pathologie-biologie, 2008

Abstract

OBJECTIVE: Retrospective study of patients presenting Aeromonas spp. infections admitted to Nîmes hospital from January 1997 to December 2004. PATIENTS AND METHOD: Aeromonas spp. infections were collected from the database of the bacteriology department. The Aeromonas species, suceptibility phenotype, epidemiological data, site and type (nosocomial or not) of infection, and evolution were collected from medical files. RESULTS: Thirty infections were notified corresponding to 22 male and eight female of 50.6 years old (mean) and a mean stay duration of 31 days. Skin and soft tissues (50%), digestive tract (26.7%), bones and articulations (10%), blood stream (6.7%), urinary tract (3.3%) and lymph nodes (3.3%) were the sites of infection. Ten infections were nosocomial, four were associated with medical leeches. All strains were resistants to amoxicillin and amoxicillin- clavulanic acid, whereas resistance rate to other beta-lactams was under 10% and all were suceptible to fluoroquinolones and aminoglycosides. All patients received antibiotic treatment: 31% a single molecule, 69% an association and 62% needed a second line treatment. Strain was suceptible to the antibiotic in 78.5% of cases. Only one death occured not directly linked to Aeromonas infection. DISCUSSION: Most of Aeromonas spp. infection sites were cutaneous and digestive. Nosocomial infections associated with medical leeches are not so uncommon and strict conditions of storage and administration are necessary. According to the susceptibility phenotype of our strains which is similar to literature data, a third generation cephalosporin or a fluoroquinolone should be used evenly associated with an aminoglycoside.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal Article
Indexed MeSH termsAdultAeromonasAgedCross InfectionFemaleFranceGram-Negative Bacterial InfectionsHospitals, UniversityHumansMaleMiddle AgedRetrospective Studies

Zusammenfassung

30 Aeromonas infections at Nimes University Hospital over 7 years: 50% cutaneous/soft tissue, 13% medical-leech associated. All amoxicillin-resistant; susceptible to 3rd-generation cephalosporins, fluoroquinolones, aminoglycosides.

Warum dies für die Hirudotherapie relevant ist

This retrospective study analyzed Aeromonas spp. infections notified at Nîmes hospital from January 1997 to December 2004, identifying 30 cases (22 male, 8 female; mean age 50.6 years; mean stay 31 days). Infection sites included skin and soft tissues (50%), digestive tract (26.7%), bones and articulations (10%), bloodstream (6.7%), urinary tract (3.3%), and lymph nodes (3.3%). Ten infections were nosocomial, and four were associated with medical leeches. All strains were resistant to amoxicillin and amoxicillin-clavulanic acid, with low resistance to other beta-lactams and universal susceptibility to fluoroquinolones and aminoglycosides; the authors suggest third-generation cephalosporins or fluoroquinolones, even associated with aminoglycosides, for treatment. This is relevant to ASH as it documents nosocomial Aeromonas infections linked to medical leech use and stresses strict storage and administration conditions. The study is a retrospective hospital database review focused on infection surveillance, not on leech therapy efficacy.

Zitation

Aeromonas spp. infections: retrospective study in Nimes University Hospital, 1997-2004.

Fraisse T et al. · Pathologie-biologie, 2008

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.